These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29747313)

  • 1. [Clinical observation of apatinib mesylate for the treatment of multi-drug resistant advanced breast cancer].
    Lü HM; Zhang MW; Niu LM; Zeng HA; Yan M
    Zhonghua Yi Xue Za Zhi; 2018 Apr; 98(16):1246-1249. PubMed ID: 29747313
    [No Abstract]   [Full Text] [Related]  

  • 2. Apatinib mesylate tablet in the treatment of advanced malignant melanoma.
    Yang L; Zhu H; Luo P; Chen S; Xu Y; Wang C
    Onco Targets Ther; 2018; 11():5333-5338. PubMed ID: 30214239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer.
    Huang W; Wang C; Shen Y; Chen Q; Huang Z; Liu J; Lin X; Wang L; Wu F; Chen X; Li N; Hong Y; Chen M; Li J; Huang C
    BMC Cancer; 2024 Jan; 24(1):39. PubMed ID: 38182995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Influence of apatinib and VEGFR2-906T>C polymorphism on clinical outcomes of advanced non-small cell lung cancer patients].
    Zhao RH; Zhou YN; Li H; Li R; Zhang WJ; Zong H
    Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):105-110. PubMed ID: 30669747
    [No Abstract]   [Full Text] [Related]  

  • 5. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
    Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
    BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment for recurrent or advanced cervical cancer patients.
    Zhang L; Chen L; Yu H
    Invest New Drugs; 2020 Aug; 38(4):1186-1191. PubMed ID: 31637668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical response and safety of apatinib monotherapy in recurrent, metastatic cervical cancer after failure of chemotherapy: a retrospective study.
    Xiao Y; Cheng H; Wang L; Yu X
    J Gynecol Oncol; 2020 Jan; 31(1):e2. PubMed ID: 31788992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial.
    Wu S; Zhang L; Li H; Xu J; Jiang C; Sun T
    Trials; 2020 May; 21(1):420. PubMed ID: 32448335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical response to apatinib monotherapy in advanced non-small cell lung cancer.
    Xu J; Liu X; Yang S; Zhang X; Shi Y
    Asia Pac J Clin Oncol; 2018 Jun; 14(3):264-269. PubMed ID: 29243413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Apatinib Treatment for Advanced Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An Open-Label Phase II Prospective Study.
    Zhang G; Gong S; Pang L; Hou L; He W
    Front Oncol; 2021; 11():659217. PubMed ID: 34012920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China.
    Li F; Liao Z; Zhao J; Zhao G; Li X; Du X; Yang Y; Yang J
    Oncotarget; 2017 Sep; 8(38):64471-64480. PubMed ID: 28969086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy.
    Liao Z; Li T; Zhang C; Liu X; Xing R; Teng S; Yang Y; Zhao G; Bai X; Zhao J; Yang J
    Cancer Biol Med; 2020 May; 17(2):501-512. PubMed ID: 32587785
    [No Abstract]   [Full Text] [Related]  

  • 13. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.
    Liu JY; Zhu BR; Wang YD; Sun X
    Int J Clin Oncol; 2020 Jun; 25(6):1195-1205. PubMed ID: 32215805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of low-dose apatinib in advanced gastric cancer: A real-world study.
    Du Y; Cao Q; Jiang C; Liang H; Ning Z; Ji C; Wang J; Zhou C; Jiang Z; Yu C; Li L; Zhao Y; Xu Y; Xu T; Hu W; Wang D; Cheng H; Wang G; Zhou J; Wang S; Zhang Y; Hu Z; Li X; Lu D; Zhang J; Xie H; Sun G
    Cancer Med; 2020 Jul; 9(14):5008-5014. PubMed ID: 32441892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of apatinib for patients with advanced extremity desmoid fibromatosis: a retrospective study.
    Zheng C; Fang J; Wang Y; Zhou Y; Tu C; Min L
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):2127-2135. PubMed ID: 33452581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study.
    Li LH; Chen WC; Wu G
    Dis Markers; 2022; 2022():4322404. PubMed ID: 35531474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apatinib is effective for treatment of advanced hepatocellular carcinoma.
    Kong Y; Sun L; Hou Z; Zhang Y; Chen P; Cui Y; Zhu X; Song T; Li Q; Li H; Zhang T; Qin L
    Oncotarget; 2017 Dec; 8(62):105596-105605. PubMed ID: 29285275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single-arm, prospective study of apatinib mesylate plus pemetrexed in patients of advanced non-squamous non-small cell lung cancer after failure of previous chemotherapy.
    Dong S; Ou W; Zhong Y; Zhu X; Cai Q; Zhang J; Ran F; Qian Y; Wang J; Hu S
    Ann Transl Med; 2022 Jan; 10(2):101. PubMed ID: 35282037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of apatinib for the treatment of gastric cancer.
    Geng R; Song L; Li J; Zhao L
    Expert Opin Drug Saf; 2018 Nov; 17(11):1145-1150. PubMed ID: 30324820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of apatinib treatment for patients with advanced or recurrent biliary tract cancer: a retrospective study.
    Nie C; Lv H; Xing Y; Chen B; Xu W; Wang J; Chen X
    BMC Cancer; 2021 Feb; 21(1):189. PubMed ID: 33622272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.